Cancer has not been cured. Not even close. Professor Kwang-Hyun Cho’s team at KAIST built a computational model of 522 genes and nearly 2,000 interactions from 4,252 intestinal cells. They ran simulations to find three genes (MYB, HDAC2, FOXA2) that, when silenced simultaneously, push colon cancer cells toward behaving like healthy intestinal tissue. The reprogrammed cells expressed normal markers like KRT20 and VDR while cancer pathways like MYC and WNT went quiet. In mice, tumors from treated cells were significantly smaller than controls. Here’s what those 8M people scrolling past aren’t processing: this worked on three colon cancer cell lines in a lab. The only cancer where “reversion therapy” has actually worked in humans is acute promyelocytic leukemia, where ATRA plus arsenic trioxide hits 95%+ complete remission. That breakthrough happened decades ago. Extending it to solid tumors has been the white whale of oncology ever since. The KAIST work is real and the computational approach using digital twins to systematically identify targets is genuinely new. Previous reversion discoveries were mostly accidental. BENEIN gives researchers a framework to screen for molecular switches across cancer types instead of stumbling into them. But the tech has been transferred to a startup called BioRevert Inc., and the gap between “cancer cells changed behavior in a dish” and “this treats cancer patients” is roughly a decade and a billion dollars of clinical trials. The cells need to stay reverted long-term, the approach needs to work inside actual human tumors with their chaotic microenvironments, and nobody yet knows if silencing MYB, HDAC2, and FOXA2 in a living patient produces side effects that rival the disease itself. The real story: KAIST built a better map. They didn’t find the destination yet.